Prevalence of Primary Aldosteronism in Patients With Resistant Hypertension in China

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Wang Weiqing, Shanghai Jiao Tong University School of Medicine
ClinicalTrials.gov Identifier:
NCT01459042
First received: October 21, 2011
Last updated: October 24, 2011
Last verified: October 2011
  Purpose

Recent studies indicate that primary aldosteronism (PA) is a much more common cause of hypertension than had been demonstrated historically. In patients with resistant hypertension, the prevalence of PA from different clinics worldwide is about 10-20%. As has been no such data in China, the investigators are conducting a PA study in different province of China to evaluate the prevalence of PA in patients with resistant hypertension.


Condition
Hypertension, Resistant to Conventional Therapy

Study Type: Observational
Study Design: Observational Model: Ecologic or Community
Time Perspective: Cross-Sectional
Official Title: Prevalence of Primary Aldosteronism and Status of Renin-Angiotensin System in Resistant Hypertension:An Observational Study in China

Resource links provided by NLM:


Further study details as provided by Shanghai Jiao Tong University School of Medicine:

Biospecimen Retention:   Samples With DNA

blood samples,including serum, plasma and whole blood.


Estimated Enrollment: 2000
Study Start Date: January 2010
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
primary aldosteronism
essential hypertension

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients with resistant hypertension from different provinces of China

Criteria

Inclusion Criteria:

  • patients with resistant hypertension
  • age 18-65 years

Exclusion Criteria:

  • known cause of hypertension
  • heart failure
  • renal dysfunction
  • Stroke, transient ischaemic attack or myocardial infarction in the past 6 months
  • cirrhosis
  • pregnancy
  • undertreatment of glucocorticoid
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01459042

Locations
China, Shanghai
Dep.endocrinology of Shanghai Ruijin Hospital, Shanghai Jiaotong university school of medcine
Shanghai, Shanghai, China, 200025
Sponsors and Collaborators
Shanghai Jiao Tong University School of Medicine
Investigators
Principal Investigator: Weiqing Wang, MD, PhD Endocrinology Department of Ruijin Hospital affiliated Shanghai Jiao Tong University School of Medicine
  More Information

No publications provided

Responsible Party: Wang Weiqing, Endocrinology Department of Ruijin Hospital affiliated Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University School of Medicine
ClinicalTrials.gov Identifier: NCT01459042     History of Changes
Other Study ID Numbers: 19830409
Study First Received: October 21, 2011
Last Updated: October 24, 2011
Health Authority: China: Ethics Committee

Additional relevant MeSH terms:
Hypertension
Hyperaldosteronism
Coronary Vasospasm
Vascular Diseases
Cardiovascular Diseases
Adrenocortical Hyperfunction
Adrenal Gland Diseases
Endocrine System Diseases
Coronary Disease
Myocardial Ischemia
Heart Diseases

ClinicalTrials.gov processed this record on September 18, 2014